Pancreatic ductal adenocarcinoma is characterized by a poor prognosis and a low median
survival, despite improvements observed for many other solid tumours. Intensive research
efforts have been undertaken during the last decades to discover new prognostic and
treatment predictive biomarkers for pancreatic ductal adenocarcinoma. The mainstay of
medical treatment for the disease has been the well-tolerated nucleoside analogue,
gemcitabine. The only targeted agent currently used in pancreatic ductal adenocarcinoma …